Your Top 10 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, Joachim Sieper, Pentti Järvinen, Lai‐Shan Tam and 10 more
- Rank
- 8 of 1,672
- Percentile
- top 0.5%
- Where
- Annals of the Rheumatic Diseases, 2018
- Citations
- 389
From the 2018 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.